Metagenomic, metabolomic, and lipidomic shifts associated with fecal microbiota transplantation for recurrent Clostridioides difficile infection/Experiment 1
From BugSigDB
Needs review
Subjects
- Location of subjects
- United States of America
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Clostridium difficile infection clostridium difficile disease,Clostridium difficile infection,clostridium difficile infection
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- pre-FMT
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- post-FMT (2 weeks)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- post-FMT (2 weeks) refers to samples from patients at 2weeks of fecal microbiota transplant (FMT).
- Group 0 sample size Number of subjects in the control (unexposed) group
- 16
- Group 1 sample size Number of subjects in the case (exposed) group
- 11
Lab analysis
- Sequencing type
- WMS
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- Not specified
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- log transformation
- Statistical test
- MaAsLin2
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- Yes
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- increased
Signature 1
Needs review
Source: Table S1
Description: Differential abundance of microbiota between pre-FMT patients and 2-weeks post-FMT patients.
Abundance in Group 1: increased abundance in post-FMT (2 weeks)
| NCBI | Quality Control | Links |
|---|---|---|
| Acutalibacteraceae | ||
| Anaerovoracaceae | ||
| Bacteroidaceae | ||
| Bifidobacteriaceae | ||
| Butyricicoccaceae | ||
| Coriobacteriaceae | ||
| Eggerthellaceae | ||
| Lachnospiraceae | ||
| Oscillospiraceae |
Revision editor(s): KateRasheed
Signature 2
Needs review
Source: Table S1
Description: Differential abundance of microbiota between pre-FMT patients and 2-weeks post-FMT patients.
Abundance in Group 1: decreased abundance in post-FMT (2 weeks)
| NCBI | Quality Control | Links |
|---|---|---|
| Enterobacteriaceae | ||
| Veillonellaceae |
Revision editor(s): KateRasheed
